Company Description
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions.
The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE.
It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 25, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 761 |
| CEO | Derek Maetzold |
Contact Details
Address: 505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 United States | |
| Phone | 866 788 9007 |
| Website | castlebiosciences.com |
Stock Details
| Ticker Symbol | CSTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001447362 |
| CUSIP Number | 14843C105 |
| ISIN Number | US14843C1053 |
| Employer ID | 77-0701774 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President and Director |
| Frank Stokes | Chief Financial Officer and Treasurer |
| Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Tobin W. Juvenal | Chief Commercial Officer |
| Camilla Zuckero | Vice President of Investor Relations and Corporate Affairs |
| Kevin Doman | Vice President of Sales |
| Dr. Jay Braxton Pharm.D. | Vice President of Marketing and Brand Manager of Uveal Melanoma (UM) |
| Keli Greenberg | Vice President of Human Resources |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2025 | 144 | Filing |
| May 23, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 5, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |
| Apr 14, 2025 | SCHEDULE 13G | Filing |
| Apr 9, 2025 | ARS | Filing |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |